ArticleInternational journal of cancer2019

Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.

Sylvia Grünewald et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.